Stock Pulse
Regeneron Pharmaceuticals (REGN) reported strong Q4 2024 results with a 10% year-over-year revenue increase to $3.79 billion, exceeding expectations [2], [4]. Full-year revenue reached $14.2 billion, driven by key products like Dupixent and Eylea [4], [6]. Despite positive earnings, REGN stock declined due to broader market turmoil and competition [2], [5]. While Eylea faces biosimilar competition and legal challenges [3], [5], Dupixent's expansion, including recent approval for COPD in Japan, and a diverse pipeline offer long-term growth potential [3], [5], [6]. The company initiated a dividend, continues share buybacks, and is investing heavily in R&D [3], [6]. While the FDA issued Complete Response Letters for two drug candidates [6], the company’s long-term prospects appear positive, with analysts projecting significant upside [3].